This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aerie Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

13.7%

수익 성장률

18.2%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	53.6%
자기자본 수익률	n/a
순이익	-17.1%
최근 수익 업데이트	30 Sep 2022

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Aerie Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:0P0 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 22	214	-37	130	88
30 Jun 22	207	-49	130	85
31 Mar 22	201	-69	137	83
31 Dec 21	194	-75	138	76
30 Sep 21	104	-166	137	74
30 Jun 21	95	-166	134	71
31 Mar 21	86	-176	133	73
31 Dec 20	83	-183	137	74
30 Sep 20	83	-192	138	76
30 Jun 20	82	-202	138	82
31 Mar 20	79	-201	139	82
31 Dec 19	70	-200	138	81
30 Sep 19	60	-196	135	87
30 Jun 19	48	-232	135	94
31 Mar 19	35	-240	134	91
31 Dec 18	24	-233	121	86
30 Sep 18	10	-240	94	98
30 Jun 18	2	-187	81	82
31 Mar 18	0	-160	65	74
31 Dec 17	0	-145	57	72
30 Sep 17	0	-116	66	48
30 Jun 17	0	-107	57	48
31 Mar 17	0	-102	49	51
31 Dec 16	0	-99	35	52
30 Sep 16	0	-90	37	51
30 Jun 16	0	-84	34	48
31 Mar 16	0	-80	32	45

양질의 수익: 0P0 is currently unprofitable.

이익 마진 증가: 0P0 is currently unprofitable.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 0P0 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.

성장 가속화: Unable to compare 0P0's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: 0P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.7%).

자기자본 수익률

높은 ROE: 0P0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company is no longer active

Aerie Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.86 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.84 loss in 2Q 2021)

Aerie Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.76 loss per share (vs US$0.91 loss in 1Q 2021)

Aerie Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.86 loss in 3Q 2020)

Recent updates

Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index

Aerie Pharmaceuticals, Inc. Announces Management Changes

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.86 loss in 3Q 2021)

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.84 loss in 2Q 2021)

Aerie Pharmaceuticals, Inc. Announces First Participant Dosed in the Comet-3 Study of Ar-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

First quarter 2022 earnings released: US$0.76 loss per share (vs US$0.91 loss in 1Q 2021)

No longer forecast to breakeven

Dr. Gerald D. Cagle to Not Stand for Re-Election as Director of Aerie Pharmaceuticals, Inc

Aerie Pharmaceuticals, Inc. Announces Retirement of Kathleen McGinley as Chief Human Resources Officer and Vice President, Corporate Services, Effective March 31, 2022

Aerie Pharmaceuticals, Inc. Announces Executive Changes

Aerie Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

Aerie Pharmaceuticals, Inc. Announces Revenue Guidance for the Full Year for 2022

Aerie Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Forecast to breakeven in 2024

Insufficient new directors

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.86 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$1.05 loss in 2Q 2020)

CFO, Secretary & Treasurer Richard Rubino has left the company

Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan

Forecast to breakeven in 2024

New 90-day high: €16.00

Full year 2020 earnings released: US$3.99 loss per share (vs US$4.39 loss in FY 2019)

Revenue beats expectations

Aerie Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €11.70

Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

New 90-day high: €11.60

Aerie Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Roclanda® in the European Union

Third quarter 2020 earnings released: US$0.86 loss per share

Revenue beats expectations

Aerie Pharmaceuticals, Inc. Announces Commencement of Comet-1

Aerie Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €8.15

Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease

Aerie Pharmaceuticals, Inc. Announces Successful Interim 90-Day Topline Data from Its Six-Month Phase 3B Clinical Trial in Europe Known as Mercury 3

New 90-day low - €8.85

New 90-day low - €9.55

First half earnings released

New 90-day low - €10.00

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기